Optimata Ltd.
Tel Aviv, IL· latest recorded location
Optimata Ltd. is named on 9 US grants and 7 published applications in this corpus. Its most frequent classification is G16H (Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the).
- Granted patents
- 9
- Published applications
- 7
- Inventors
- 22
- Granted in 2026 so far
- 0
- Most recent grant
- 11 Feb 2014
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 1 | 0 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 2 | 1 |
| 2012 | 0 | 1 |
| 2013 | 2 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
By publication year.
Technology areas
Share of 16 documents
- G16HHealthcare informatics, i.e. information and communication technology [ict] specially adapted for the11
- A61PTherapeutic uses of medicines8
- G16CComputational chemistry5
- G01NInvestigating or analysing materials by determining their chemical or physical properties3
- G01FMeasuring volume, volume flow, mass flow or liquid level2
- A61KMedicines and medical preparations1
- G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or1
Recent patents
- System and method of evaluation of stochastic interactions of a soluble ligand with a target cell population for optimization of drug design and delivery11 Feb 2014US 8,650,017 B2
- System and methods for optimized drug delivery and progression of diseased and normal cells6 Aug 2013US 8,504,303 B2
- Techniques for purposing a new compound and for re-purposing a drug16 Jul 2013US 8,489,336 B2
- System and methods for optimized drug delivery and progression of diseased and normal cells8 Nov 2011US 8,055,491 B2
- Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV28 Jun 2011US 7,970,550 B2
- System and method for prediction of medical treatment effect8 Oct 2020US 2020/0321091 A1
- Method and system for prediction of medical treatment effect18 May 2017US 2017/0140109 A1
- System and methods for optimized drug delivery and progression of diseased and normal cells8 Nov 2012US 2012/0284005 A1
- Cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)24 Nov 2011US 2011/0286960 A1
- Techniques for Purposing a New Compound and for Re-Purposing a Drug24 Jun 2010US 2010/0161301 A1
Most cited
By later US patents
- Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV32US 7,970,550 B22011
- System and methods for optimized drug delivery and progression of diseased and normal cells24US 6,871,171 B12005
- System and methods for optimized drug delivery and progression of diseased and normal cells3US 7,133,814 B22006
- System and method of evaluation of stochastic interactions of a soluble ligand with a target cell population for optimization of drug design and delivery2US 8,650,017 B22014
- System and methods for optimized drug delivery and progression of diseased and normal cells1US 7,266,483 B22007